文献速递类风湿关节炎系统性红斑狼疮

类风湿关节炎与系统性红斑狼疮患者抗疟药依从性与心血管事件风险:一项基于人群的研究

Antimalarial Adherence and Risk of Cardiovascular Events in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-Based Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2023-12-18

在加拿大不列颠哥伦比亚省1997年1月至2015年3月新诊断类风湿关节炎或系统性红斑狼疮且新启用抗疟药的患者中,评估抗疟药依从性与心血管事件(心肌梗死、卒中或静脉血栓栓塞)的关联。平均随访9年,依从(PDC≥0.90)相对于停药的心血管事件调整风险比为0.72,相对于非依从为0.71。

要点

  • 抗疟药依从(PDC≥0.90)相对于停药,心血管事件aHR为0.72(95%CI 0.64-0.81)。
  • 抗疟药依从相对于非依从,心血管事件aHR为0.71(95%CI 0.61-0.82)。
  • 年龄较大修饰了抗疟药依从性与心血管事件的关联(P=0.02)。

核心结论

  • 新诊断类风湿关节炎或系统性红斑狼疮患者规律按处方服用抗疟药(PDC≥0.90)者,其发生心血管事件的风险较依从性较低(PDC<0.90)者低29%,较停药者低28%。

研究设计与样本

  • 基于人群的队列研究,使用加拿大不列颠哥伦比亚省省级行政数据库识别1997年1月至2015年3月间新诊断类风湿关节炎或系统性红斑狼疮且新启用抗疟药的患者。
  • 共纳入16,538例基线无心血管事件的新诊断类风湿关节炎或系统性红斑狼疮且新启用抗疟药者,平均随访9年。
  • 暴露为抗疟药依从性,分为停药(PDC=0)、非依从(0<PDC<0.90)和依从(PDC≥0.90)三个水平。
  • 采用边际结构模型估计抗疟药依从性对心血管事件发生率的影响,并校正潜在混杂因素。

主要发现

  • 平均随访9年期间,共观察到2,174例新发心血管事件(13.2%)。
  • 抗疟药依从相对于停药,新发心血管事件的aHR为0.72(95%CI 0.64-0.81);非依从相对于停药的aHR为1.01(95%CI 0.90-1.14)。
  • 抗疟药依从相对于非依从,所有心血管事件的aHR为0.71(95%CI 0.61-0.82),心肌梗死为0.62(95%CI 0.51-0.75),卒中为0.45(95%CI 0.36-0.58),静脉血栓栓塞为0.65(95%CI 0.46-0.93)。
  • 年龄较大修饰了抗疟药依从性与心血管事件之间的关联(P=0.02)。

临床怎么用

  • 原文结论指出,新诊断类风湿关节炎或系统性红斑狼疮患者规律按处方服用抗疟药(PDC≥0.90)时,心血管事件风险较依从性较低(PDC<0.90)者低29%,较停药者低28%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to assess the association between antimalarial adherence and cardiovascular events between incident rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) population-based cohorts. METHODS: All patients with incident RA/SLE and incident antimalarial use in British Columbia, Canada, between January 1997 and March 2015 were identified using provincial administrative databases. The outcomes were incident cardiovascular events, including myocardial infarction (MI), stroke, or venous thromboembolism (VTE). The exposure was antimalarial adherence with levels: discontinuation (proportion of days covered [PDC = 0]), nonadherence (0 < PDC < 0.90), and adherence (PDC ≥ 0.90). We used marginal structural models to estimate the effect of antimalarial adherence on the rate of cardiovascular events, accounting for potential confounders. RESULTS: We identified 16,538 individuals with incident RA/SLE and incident antimalarial use without any cardiovascular event before the index date. Over nine years mean follow-up, 2,174 incident cardiovascular events (13.2%) were observed. The adjusted hazard ratio (aHR) for incident cardiovascular events for antimalarial adherence relative to discontinuation was 0.72 (95% confidence interval [CI] 0.64-0.81) and 1.01 (95% CI 0.90-1.14) for nonadherence. Additionally, the aHRs for all cardiovascular events, MI, stroke, and VTE for adherence relative to nonadherence was 0.71 (95% CI 0.61-0.82), 0.62 (95% CI 0.51-0.75), 0.45 (95% CI 0.36-0.58), and 0.65 (95% CI 0.46-0.93), respectively. We found older age modified the association between antimalarial adherence and cardiovascular events (P = 0.02). CONCLUSION: When people newly diagnosed with RA or SLE take their antimalarial regularly as prescribed (PDC ≥ 0.90), they have a 29% lower risk of sustaining a cardiovascular event than patients with a lower degree of adherence (PDC < 0.90) and a 28% lower risk than if they discontinue antimalarials.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Hoque MR, Aviña-Zubieta JA, Lacaille D, et al. Antimalarial Adherence and Risk of Cardiovascular Events in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-Based Study. Arthritis Care Res (Hoboken). 2023. PMID: 37691305. doi:10.1002/acr.25233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。